CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.-Reference-Cited by-同舟云学术

CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:9501-9501
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Himelstein Andrew Louis¹,Qin Rui²,Novotny Paul J.²,Seisler Drew K.²,Khatcheressian James L.³,Roberts John D.⁴,Grubbs Stephen S.¹,O'Connor Tracey⁵,Weckstein Douglas⁶,Loprinzi Charles L.⁷,Shapiro Charles L.⁸

Affiliation:

1. Helen F. Graham Cancer Center & Research Institute, Newark, DE

2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

3. Virginia Cancer Institute, Richmond, VA

4. Yale University, New Haven, CT

5. Roswell Park Cancer Institute, Buffalo, NY

6. New Hampshire Onc-Hem PA, Hooksett, NH

7. Mayo Clinic, Rochester, MN

8. Mount Sinai School of Medicine, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.9501

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India;JCO Global Oncology;2024-03

2. Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group;2023-04-27

3. Role of Bisphosphonates in Breast Cancer Therapy;Current Treatment Options in Oncology;2019-03-14

4. Controversies in the Management of Solid Tumor Bone Metastases;Controversies in Radiation Oncology;2019

5. Management of Bone Metastases in Breast Cancer;The Breast;2018